Kornimate/medical-research-clean huggingface dataset:
study of real clinical practice to evaluate the effects of oral dydrogesterone for treatment of confirmed endometriosis

Conditions: Endometriosis

Summary: a non-interventional, observational program to assess the effects of dydrogesterone (duphaston®) 6-months-administration in patients with confirmed endometriosis in a post-marketing setting in the russian federation

a non-interventional, observational program to assess the effects of oral dydrogesterone therapy in a post-marketing setting whether the effects are related to the regimen of dydrogesterone therapy. in this observational program, assuming that dydrogesterone plays a role in the treatment of endometriosis without suppression of ovulation, the goal is to observe the possible implications of such treatment in terms of treatment regimen and response pattern. in the study will be described effects of duphaston® 6-months-administration in patients with confirmed endometriosis by assessing pain relief, quality of life, need of self-medication with analgesics, etc.

Eligibility criteria:
inclusion criteria: * female, aged ≥ 18 years and ≤ 45 years. * complaints on chronic pelvic pain with or without dysmenorrhea assessed by 11-items nrs. * external genital endometriosis confirmed by laparoscopy. * existing pelvic (vaginal) ultrasound data not earlier than 2 months before inclusion in the study. * prescribed treatment with duphaston® according local labelling for treatment of endometriosis 10 mg 2-3 times a day from the 5th to the 25th day of the menstrual period cycle or continuously. * no hormonal treatment in 2 cycles before enrollment. * signed patient authorization for use/disclosure of data. exclusion criteria: * any co-existing disease(s) needing chronic drug therapy (e.g. crohn's disease, diabetes etc); severe concomitant medical illness. * severe other genital pathology excluding endometriosis (e.g. multiple/severe myoma; adenomyosis, inflammatory diseases, etc.). * routine consumption of analgesics other than for the pain of endometriosis. * patients receiving hormonal contraceptives in last 2 cycles (including intrauterine devices, contraceptive patches, contraceptive rings, oral contraceptives etc.). * ongoing pregnancy. * menopause or premature ovarian failure. * contraindications to dydrogesterone treatment listed in the locally approved label (instructions for the medical use of duphaston®). * any other condition that precludes use of dydrogesterone in a particular patient, in accordance with the precautions and special warnings listed in the locally approved label (instructions for the medical use of duphaston®). * abnormal results of pap smear test. * other conditions that made the patients participation impossible (based on the investigator decision). * fertility treatments using assisted reproductive technology.

Keywords: endometriosis dydrogesterone duphaston® progestogens pelvic pain
hip activation and fsdt

Conditions: Movement, Abnormal; Lower Extremity Problem

Summary: the purpose of this study is to determine if activation training of the hip musculature affects muscle activation and frontal plane mechanics in healthy individuals. specific aim 1: determine whether performance on the forward step-down test (fsdt) changes after an eight-week home exercise program (hep) focused on hip musculature activation in healthy individuals. specific aim 2: determine whether surface electromyography (semg) hip musculature changes following an eight-week hep focused on hip musculature activation in healthy individuals. specific aim 3: determine whether a dose-response relationship exists between compliance on the hep and changes in fsdt scores in healthy individuals. specific aim 4: determine whether a dose-response relationship exists between compliance on the hep and semg changes in hip musculature activation in healthy individuals.


Eligibility criteria:
inclusion criteria: * participants must be current first or second year doctor of physical therapy students in the school of allied health professions at lsu health shreveport. exclusion criteria: * current knee pain or pathology in the dominant leg, and women with known pregnancy.
intensive prevention program after myocardial infarction

Conditions: Myocardial Infarction; Prevention Harmful Effects

Summary: it is unknown, if a modern prevention program, including intense nurse-coordinated education sessions, regular telephone contacts and a telephone hotline for 12 months, significantly reduces cardiovascular risk factors, clinical events and quality of life in myocardial infarction patients compared to usual care. furthermore, actually no data on the additional effects and the feasibility of longterm telemetric care of cardiovascular risk factors exist. the primary hypothesis to be tested is that an intensive longterm prevention program compared to the standard of medical care, will achieve better risk factor control and consecutively less clinical adverse events in patients after myocardial infarctions. the study endpoints will be evaluated after 12 months and during long-term course (after 24 months = one year after termination of the prevention program). in a substudy the effects of short reinterventions ("prevention boosts") during long-term course are tested (ipp prevention boost study). patients with at least one insufficiently controlled risk factor at 24-months visit are randomly assigned to a short (2-month) reintervention vs. no reintervention. the effects of the reinterventions on risk factor control are evaluated after 36 months. a further substudy focusing on young patients \<= 45 years of age at time of mi (ipp-y = ipp in the young) was added after completion of the pilot ipp study. in this study we focus on the prevention program in young mi-patients. a retrospective analysis of individual genetic risk (assessed by genetic risk scores) in the young patients is included in this substudy.


Eligibility criteria:
inclusion criteria: hospitalisation due to myocardial infarction (st-elevation or non-st-elevation myocardial infarction) exclusion criteria: i) hemodynamically significant valvular heart disease (\> nyha class ii) or inborn cardiac malformations. ii) cardiomyopathy associated with hemodynamic obstruction, pregnancy or myocarditis. iii) exercise limitations due to clinical conditions not related to cad. iv) any major non-cardiac condition that would adversely effect survival during the duration of the study. v) patients unlikely to comply to the study treatment and the follow-up visits. vi) pregnancy (all pre-menopausal females should have a negative serum pregnancy test). vii) inability of cooperation with the protocol, including longterm follow-up. viii) patient refusal or inability to give informed consent. ix) refusal of the patient's physician regarding trial participation of the patient. x) chronic drug or alcohol abuse.
single-incision laparoscopic surgery in acute abdomen

Conditions: Acute Appendicitis

Summary: since semm et.al. reported the first case of laparoscopic appendectomy in 1983, minimally invasive surgery has become the main stay for treating of many surgical diseases. after the booming in the advancement of surgical instrument and breakthrough in surgical skills, the minimally invasive surgery has been widely applied to neurosurgery, spinal surgery, breast, thyroid, hernia surgery, etc. it has been proved that minimally invasive surgery is safe and effective, and further it achieves compatible results and outcomes in oncology and functional diseases. minimally invasive surgery in alimentary tract, known as laparoscopic surgery, has been performed in gastric surgery (e.g. gastric cancer, tumor, functional disorders and bariatric surgery), hepatobiliary and pancreatic surgery (e.g. hepatectomy, cholecystectomy, and pancreatectomy), and colorectal surgery (e.g. colorectal cancer and functional bowel disease). under a superior heritage of surgical skills from taiwan university hospital, we introduced laparoscopic surgery in 1996 and currently, laparoscopic surgery becomes the mainstay of surgery in yunlin branch. in 2015, there were 600 laparoscopic surgery in our hospital, while 150 colorectal laparoscopic surgery in the same year. in recent years, single-incisional laparoscopic surgery has emerged to become one of the focused topic in the world and seemly in our department. through single-incision surgery, we attempted to minimize the incision wound to achieve better cosmesis and faster recovery. by the valuable clinical experiences gathering in our hospital (yunlin branch) in recent 10 years, we contemplate two-step plans: first, by retrospective data collection, we can explain the clinical problems based on current statistical results. second, based on prior (step 1) retrospective findings, a prospective study could be conducted for more evident results.

the aim of this study is to compare two kinds of single-incision laparoscopic surgery setting including hand-made glove setting and commercialized single-incision multiport setting. the preoperative, intraoperative and postoperative data will be collected for analysis.

Eligibility criteria:
inclusion criteria: 1. the patients admitted to the ntuh yunlin branch diagnosed clinically as acute appendicitis 2. the patients with clinically suspected right lower quadrant pain and acute appendicitis could not be excluded exclusion criteria: 1. not eligible to underwent laparoscopic surgery because of compromised cardiopulmonary function or major laparotomy surgery 2. decide to receive non-surgical treatment of the acute appendicitis 3. age\<20, or could not exercise the right of autonomy or unwilling to participate the study

Keywords: laparoscopic appendectomy single-incision laparoscopic appendectomy single-incision laparoscopic surgery setting simple appendicitis complicated appendicitis
micro vs. standard trabeculectomy study

Conditions: Glaucoma

Summary: the purpose of this study is to determine the reduction in intraocular pressure and cumulative incidence of complications between the standard and micro trabeculectomy surgeries 3 months after surgery.

this study is a randomized, double-masked (study participants and outcome assessors) trial. during the enrollment period, consecutive patients from lei who are planning to have trabeculectomy surgery and who meet the study enrollment criteria will be randomized to receive standard trabeculectomy or microtrabeculectomy. the primary outcome is complications and change in intraocular pressure after a 3 month follow-up period. we will perform subgroup analyses by stratifying the population according to skin pigmentation to determine whether pigmentation is a predictor of treatment success.

Eligibility criteria:
inclusion criteria: * age \>= 40 * planning to have a trabeculectomy exclusion criteria: * life threatening or debilitating disease * inability to complete necessary exams and/or ocular disease that would preclude assessment of intraocular pressure, visual field, or optic disc * contralateral eye already enrolled in study

Keywords: glaucoma trabeculectomy eye disease intraocular pressure visual acuity
safety and efficacy of neuroform3tm for intracranial aneurysm treatment

Conditions: Intracranial Aneurysm

Summary: this is a prospective observational multicenter registry to evaluate safety and efficacy data on neuroform3tm stenting for treatment with endovascular coiling of wide neck aneurysms on an intent to treat basis. the objectives of this study are: 1. assessment of morbidity-mortality at 1 month and 12-18 months following the treatment of the intracranial aneurysm with neuroform3tm stent and endovascular coiling using the modified rankin scale (mrs). 2. to evaluate adverse events. 3. angiographic assessment at 12-18 months compared to the initial post-treatment assessment via the modified raymond scale and same/better/worse scale.

there is an increasing perception in the neurovascular community - supported by extensive peer-to-peer and congress communications - that "stent-assisted coiling" of intracranial wide neck aneurysms improves the long term angiographic outcome of treated patients.

Eligibility criteria:
inclusion criteria: * 18 year's old patient or above. * every patient suffering from an un-ruptured or ruptured aneurysm, for whom the endovascular treatment approach using the neuroform3tm stent is considered by the therapeutic team in charge. * patient who has given his consent to participate to the study and to get his anonymized data collected exclusion criteria: * patient with dissecting or fusiform aneurysm * treatment of several aneurysms in the same procedure, except adjacent aneurysm treated by the same stent * severe vasospasm * aneurysm associated with an arterio-venous malformation * use of another neuroform3tm stent * woman pregnant or nursing * patients not likely to be followed upon (living abroad) * people protected by justice (safeguard of law, supervision or trusteeship) * patient unsuitable to the anti-thrombotic and/or to anticoagulants therapies

Keywords: intracranial stenting endovascular treatment stent-assisted coiling cerebrovascular disease
treatment of postpartum urinary retention

Conditions: Retention, Urinary

Summary: the aim of the study is to evaluate what is the most effective catheterization duration to resolve covert and overt postpartum urinary retention following vaginal delivery and caesarean delivery, with the highest patients' satisfaction.

1. women who are unable to micturate for more than 6-8 hours following vaginal delivery or within six to eight hours following removal of an indwelling catheter after cesarean delivery (overt postpartum urinary retention), or women with postvoid residual bladder volume of at least 150 ml (covert postpartum urinary retention) will be randomized into 2 groups: one group will include women who are catheterized intermittently every 6-8 hours up to a total time of 48 hours. if at any time, post voiding residual volume is less than 150cc (assessed by ultrasound or by catheterization), no additional catheterization is needed. the second group will include women which will have an indwelling catheter inserted for 24 hours. the catheter will be removed 24 hours following its insertion and post voiding residual volume will be assessed 6 hours following the catheter removal (by ultrasound or by catheterization). in cases of post voiding residual volume more than 150 cc or women are unable to micturate spontaneously, an indwelling catheter will be inserted for additional 24 hours. 2. after 48 hours from postpartum urinary retention diagnosis, an indwelling catheter will be inserted for additional time that will be set at every center by its common protocol.

Eligibility criteria:
inclusion criteria: * women who deliver at one of the centers included in the study * overt postpartum urinary retention which refers to the absence of spontaneous micturition within six to eight hours of vaginal delivery; or within six to eight hours following removal of an indwelling catheter after cesarean delivery * covert postpartum urinary retention diagnosed by ultrasound or catheterization of more than 150cc exclusion criteria: * spontaneous micturition 6-8 hours following vaginal or cesarean delivery * postpartum urinary retention less than 150cc on ultrasound * known urinary tract infection
zenith® low profile aaa endovascular graft

Conditions: Abdominal Aortic Aneurysms; Iliac Aneurysms; Aortoiliac Aneurysms

Summary: the zenith® low profile aaa endovascular graft clinical study is a clinical trial to study the safety and effectiveness of the zenith® low profile aaa endovascular graft used in conjunction with the zenith® spiral-z® aaa iliac leg graft to treat abdominal aortic, aortoiliac, and iliac aneurysms.


Eligibility criteria:
inclusion criteria: * subject has at least one of the following * aortic or aortoiliac aneurysm * iliac aneurysm * aneurysm with a history of growth exclusion criteria: * less than 18 years of age * inability or refusal to give informed consent * disease considerations that would compromise patient safety or study outcomes * pregnant of breastfeeding or planning on becoming pregnant with 60 months * unwilling to comply with the follow-up schedule

Keywords: low profile abdominal aortic aneurysms endovascular
impact of curcumin and pentoxiphylline on chronic kidney disease patients

Conditions: Chronic Kidney Disease

Summary: the aim of the study is to evaluate the impact of turmeric and pentoxiphylline on serum levels of protein-bound uremic toxin (p-cresyl sulfate), oxidative stress biomarker level (malonaldehyde), inflammatory biomarker level (highly sensitive c-reactive protein). in addition to the evaluation of its effect on metabolic profile and disease progression in chronic kidney disease patients.

1. ethical committee approval has been obtained from ethics committee of faculty of medicine, alexandria university. 2. all participants should agree to take part in this clinical study and will provide informed consent. 3. sixty chronic kidney disease patients will be recruited from the kidney and urology center (kuc) and alexandria main university hospital (amuh). the 60 participants will be randomly assigned into 3 arms. group 1 (control group; n=20): patients will be treated with standard care only for 6 months. group 2 (n=20): patients will be treated with the same standard care plus curcumin capsules 500 mg twice daily for 6 months. group 3 (n=20): patients will be treated with the same standard care plus pentoxiphylline 400 mg twice daily for 6 months. 4. all patients will be submitted to : full patient history and clinical examination. blood withdrawal in order to conduct lab work. 5. patients demographic data will be recorded with respect to age, weight and other co-morbidities. 6. statistical tests appropriate to the study design will be conducted to evaluate the significance of the results. 7. results, conclusion, discussion and recommendations will be given.

Eligibility criteria:
inclusion criteria: * age ≥ 18 years old. * both sexes. * non-hemodialysis ckd patients (stage iii -v) * patients matched in the duration of ckd. * patients with albumin-to-creatinine ratio ≥ 30 mg/g. * patients with serum potassium \< 5 meq/l exclusion criteria: * patients with elevated level of potassium ≥ 5 meq/l. * patients with cancer. * patients with kidney stones and urinary tract infection. * patients with bleeding disorder. * history of drug allergy to study medications. * pregnant and breastfeeding women.

Keywords: curcumin pentoxiphylline chronic kidney disease
self-compassion enhanced cbt vs. standard cbt for social anxiety (sce-cbt)

Conditions: Social Anxiety Disorder

Summary: this study evaluates the addition of a self-compassion training in the treatment of social anxiety disorder. half of the participants will receive a self-compassion enhanced group cognitive-behavioral therapy, while the other half will receive standard group cognitive-behavioral therapy.

there is growing evidence showing that shame is associated with social anxiety. also, empirical data shows that individuals with social anxiety have higher levels of shame compared with healthy individuals and that shame might play an important role in the maintenance of social anxiety symptoms. although cognitive-behavioral therapy for social anxiety seems to reduce the level of shame-proneness, the magnitude of this reduction is a small one. the purpose of this study is to test whether adding a self-compassion component (which seems to be effective in reducing shame feelings) to a cognitive-behavioral protocol would increase the efficacy of the treatment in reducing both shame-proneness and social anxiety symptoms compared with a standard cognitive-behavioral intervention.

Eligibility criteria:
inclusion criteria: * subjects diagnosed with social anxiety disorders using the dsm-5 criteria * subjects that have sad as the primary diagnosis according to dsm-5 criteria * exceed the cutoff scores on spin, sias, and lsas-sr exclusion criteria: * subjects that score over 29 points at bdi-ii * display suicidal ideation (i.e., exceed a score of 2 on the suicide item of bdi-ii) * undergo other forms of treatment for sad * have a diagnosis of psychosis, bipolar disorder or personality disorders according to dsm-5 criteria

Keywords: social phobia compassion shame
effect of cpap on biomarkers in patients with osa

Conditions: Obstructive Sleep Apnea

Summary: cpap, the standard treatment for obstructive sleep apnea syndrome (osas) that reduces sleep fragmentations and neurocognitive deficit in osas may also have a key role in reduction of cardiovascular, mortality risks in the same patients.

obstructive sleep apnea (osa) is a condition in which there is collapse of the upper airway during sleep, as a result of which there is a decrease or complete cessation of airflow. this leads to repeated episodes of hypoxia during sleep and sleep fragmentation. it is a highly prevalent though under-recognized clinical problem.there is increasing evidence that inflammation plays important role in development of cardiovascular complications in patients with osa. continuous positive airway pressure (cpap) is the standard treatment for osa with significant symptoms.however, it is a costly treatment option and poor compliance is an important limiting factor. cpap treatment has been shown to improve the daytime somnolence and neurocognitive function in people with osas. however, its effect on cardiovascular biomarkers in people with osas has not been satisfactorily assessed. this study aims to assess the effect of cpap treatment on cardiovascular biomarkers in osa.

Eligibility criteria:
inclusion criteria: the 1st part of the study will include 1. males and females, aged 30-65 years, 2. with ahi \>5 and excessive daytime sleepiness 3. naïve to cpap treatment. 4. subjects from first part of the study who have moderately severe osas and have never received treatment for osa,diabetes mellitus and hypertension exclusion criteria: 1. hypothyroidism 2. chronic renal failure 3. chronic liver disease 4. chronic lung disease 5. known systemic inflammatory diseases (lupus , sarcoidosis and other connective tissue disorders), 6. use of drugs that influence urinary protein excretion (eg. steroids, lithium, nsaids, ace inhibitors/angiotensin receptor blockers etc.) 7. immune deficiency conditions 8. pregnancy 9. active menstruation at time of sampling 10. macroalbuminuria (aacr\>300mg/g), 11. patients of coronary artery disease and left ventricular dysfunction 12. not on treatment for hypertension, diabetes mellitus or dyslipidemia 13. long lasting hypertension or diabetes mellitus (more than 5 years after diagnosis)

Keywords: obstructive sleep apnea cytokine levels insulin resistance hypertension dyslipidemia albumin-creatinine ratio continuous positive airway pressure (cpap)